Business
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 201
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 201.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it has signed a Memorandum of Understanding (“MOU”) for the distribution of its patented Lodonal™ in Côte d’Ivoire (the Ivory Coast).\n The MOU is between Immune Therapeutics, GB Pharma Holdings and Rougier Pharma Afrique SA and sets forth a framework for the future standard terms and conditions for distributing Lodonal in Côte d’Ivoire. With a population of 27 million, Cote d’Ivoire has the fastest growing economy of the African continent and the third-fastest in the world in 2016, and the African Development Bank (AfDB) projects the country’s GDP to grow at approximately 8.3% in 2017. Côte d’Ivoire has experienced an impressive turnaround since 2011, with economic growth averaging about 9% per year. The economic outlook remains strong and is supported by strategies explained in the ‘National Development Plan (NDP) 2016-20’. The NDP prioritizes inclusive and sustainable growth; focusing on structural transformation and improving quality of life for all Ivorians. The issuance of a Certificate of Pharmaceutical Product (“COPP”) has granted the Company a license to export Lodonal to Côte d’Ivoire, which has been authorized by the Dominican Republic Ministry of Public Health.  Now the Company is ready to submit a New Drug Application (“NDA”) to Directorate of Pharmacy and Medicines. The application will include the following information, COPP, Proof of cGMP, Certificate of Analysis, Dossier, Patient Data Sheet, Packaging and all clinical data supporting the request for approval.  Included with the clinical data were the results of four phase II clinical trials and one bridging trial clinical trials HIV/AIDS with more than 500 patients, as well as 89 patients for cancer, 250 patients for autoimmune and inflammation diseases.  The Company plans to position Lodonal within the Pharmacie de la Santé Publique (PSP) as an immune booster and adjunct immune therapy for cancer and HIV/AID...